We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

174 hedge funds and large institutions have $1.86B invested in Celldex Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 66 increasing their positions, 48 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more call options, than puts

Call options by funds: $24.9M | Put options by funds: $17.1M

38% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 48

2.75% more ownership

Funds ownership: 108.33% → 111.07% (+2.7%)

6% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 36

1% less funds holding

Funds holding: 176 → 174 (-2)

24% less capital invested

Capital invested by funds: $2.44B → $1.86B (-$579M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
174
Holders Change
-2
Holders Change %
-1.14%
% of All Funds
2.29%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
34
Increased
66
Reduced
48
Closed
36
Calls
$24.9M
Puts
$17.1M
Net Calls
+$7.83M
Net Calls Change
-$17.5M

Top Buyers

1
JFG
Jefferies Financial Group
New York
+$64.4M
2
KCM
Kynam Capital Management
New Jersey
+$43.6M
3
DTC
Deep Track Capital
Connecticut
+$41.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$25.7M
5
Morgan Stanley
Morgan Stanley
New York
+$24.7M

Top Sellers

1
CC
Commodore Capital
New York
-$55M
2
Jennison Associates
Jennison Associates
New York
-$45M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$31.7M
4
PCH
Polar Capital Holdings
United Kingdom
-$31.4M
5
LGM
Logos Global Management
California
-$30.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
LGM
176
Logos Global Management
California
– -$30.6M -900,000 Closed
EC
177
EcoR1 Capital
California
– -$22.1M -650,000 Closed
EA
178
Emerald Advisers
Pennsylvania
– -$15.5M -456,202 Closed
Marshall Wace
179
Marshall Wace
United Kingdom
– -$9.41M -276,728 Closed
EMFAT
180
Emerald Mutual Fund Advisers Trust
Pennsylvania
– -$8.29M -243,795 Closed
Balyasny Asset Management
181
Balyasny Asset Management
Illinois
– -$2.94M -86,573 Closed
AGP
182
Artia Global Partners
Florida
– -$2.56M -75,300 Closed
Prudential Financial
183
Prudential Financial
New Jersey
– -$2.33M -68,471 Closed
State of New Jersey Common Pension Fund D
184
State of New Jersey Common Pension Fund D
New Jersey
– -$1.79M -52,615 Closed
PHS
185
PFM Health Sciences
California
– -$1.77M -52,120 Closed
Man Group
186
Man Group
United Kingdom
– -$1.22M -35,967 Closed
YIH
187
Y-Intercept (HK)
Hong Kong
– -$1.04M -30,538 Closed
AA
188
AlphaCentric Advisors
Puerto Rico
– -$1.02M -30,000 Closed
MF
189
Magnetar Financial
Illinois
– -$867K -25,513 Closed
Assenagon Asset Management
190
Assenagon Asset Management
Luxembourg
– -$712K -20,946 Closed
GCP
191
GSA Capital Partners
United Kingdom
– -$548K -16,114 Closed
PD
192
Point72 (DIFC)
United Arab Emirates
– -$480K -14,114 Closed
CAC
193
Cowen and Company
New York
– -$364K -10,700 Closed
HS
194
HighVista Strategies
Massachusetts
– -$305K -8,981 Closed
OMC
195
Overbrook Management Corp
New York
– -$232K -6,837 Closed
PIA
196
Panoramic Investment Advisors
Colorado
– -$221K -6,500 Closed
KeyBank National Association
197
KeyBank National Association
Ohio
– -$216K -6,356 Closed
ACM
198
ADAR1 Capital Management
Texas
– -$170K -5,000 Closed
Acadian Asset Management
199
Acadian Asset Management
Massachusetts
– -$156K -4,591 Closed
PAS
200
Point72 Asia (Singapore)
Singapore
– -$41.1K -1,210 Closed
5 6 7
8
9

CLDX Hedge Fund Activity: Q4 2024 in Review

174 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2024, worth a combined $1.86B — down 24% from $2.44B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CLDX and 34 opened new positions — a net loss of 2 holders — while 48 trimmed existing stakes and 66 added.

The largest buyer was Jefferies Financial Group, adding an estimated $64.4M. The largest seller was Commodore Capital, exiting entirely with an estimated $55M sold.

  • 174 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2024, down from 176 in Q3 2024.
  • Funds reported $1.86B of Celldex Therapeutics stock for Q4 2024, down 24% quarter-over-quarter.
  • 34 funds opened new Celldex Therapeutics positions in Q4 2024 and 36 closed out, a net change of -2 holders.
  • The largest Celldex Therapeutics buyer in Q4 2024 was Jefferies Financial Group, an estimated $64.4M added.
  • The largest Celldex Therapeutics seller in Q4 2024 was Commodore Capital, an estimated $55M sold.

Based on aggregated 13F filings for Q4 2024.